Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CB11
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
CB11 is a small molecule mitochondrial protectant and potent inducer of mitochondrial biogenesis. Originally identified from a ChemBridge DiverSET library screen, CB11 has been shown to preserve mitochondrial capacity, reduce mitochondrial fission, and promote mitochondrial fusion. It is being investigated for the treatment of acute kidney injury (AKI), chronic kidney disease (CKD), and retinal degenerative diseases, such as retinitis pigmentosa and age-related macular degeneration.
- Other names
- 1-butyl-3-hydroxy-3-[2-oxo-2-(pyridin-2-yl)ethyl]-1,3-dihydro-2H-indol-2-one1-butyl-3-hydroxy-3-[2-oxo-2-(pyridin-2-yl)ethyl]indolin-2-one
Beyond the preview
Go deeper on CB11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CB11.